CR20210532A - Protacs que degradan el receptor de estrógeno - Google Patents

Protacs que degradan el receptor de estrógeno

Info

Publication number
CR20210532A
CR20210532A CR20210532A CR20210532A CR20210532A CR 20210532 A CR20210532 A CR 20210532A CR 20210532 A CR20210532 A CR 20210532A CR 20210532 A CR20210532 A CR 20210532A CR 20210532 A CR20210532 A CR 20210532A
Authority
CR
Costa Rica
Prior art keywords
protacs
estrogen receptor
receptor degrading
compounds
treatment
Prior art date
Application number
CR20210532A
Other languages
English (en)
Inventor
Charlene Fallan
Bernard Christophe Barlaam
Bin Yang
Thomas George Christopher Hayhow
James Stewart Scott
Coura Diene
Johannes Wilhelmus Maria Nissink
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR20210532A publication Critical patent/CR20210532A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (I) y sales farmacéuticamente aceptables de los mismos, donde R1, R2, R3, R4, R6, R7, R8, enlazador, A, G, D y E tienen cualquiera de los significados definidos en la presente. Esta memoria descriptiva también se refiere al uso de tales compuestos y sales farmacéuticamente aceptables de estos en métodos de tratamiento del cuerpo humano o animal, por ejemplo, en la prevención o el tratamiento del cáncer. Esta memoria descriptiva también se refiere a procesos y compuestos intermedios implicados en la preparación de dichos compuestos y a composiciones farmacéuticas que los contienen.
CR20210532A 2019-03-29 2020-03-27 Protacs que degradan el receptor de estrógeno CR20210532A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825924P 2019-03-29 2019-03-29
PCT/EP2020/058702 WO2020201080A1 (en) 2019-03-29 2020-03-27 Estrogen receptor degrading protacs

Publications (1)

Publication Number Publication Date
CR20210532A true CR20210532A (es) 2022-02-10

Family

ID=70050126

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210532A CR20210532A (es) 2019-03-29 2020-03-27 Protacs que degradan el receptor de estrógeno

Country Status (24)

Country Link
US (1) US20220169643A1 (es)
EP (1) EP3947376A1 (es)
JP (1) JP2022526370A (es)
KR (1) KR20210146984A (es)
CN (1) CN113646306A (es)
AR (1) AR118515A1 (es)
AU (1) AU2020252116B2 (es)
BR (1) BR112021019007A2 (es)
CA (1) CA3133763A1 (es)
CL (1) CL2021002489A1 (es)
CO (1) CO2021013927A2 (es)
CR (1) CR20210532A (es)
DO (1) DOP2021000198A (es)
EA (1) EA202192553A1 (es)
EC (1) ECSP21077887A (es)
IL (1) IL286461A (es)
JO (1) JOP20210259A1 (es)
MA (1) MA55495A (es)
MX (1) MX2021011811A (es)
PE (1) PE20220131A1 (es)
SG (1) SG11202110527RA (es)
TW (1) TW202102497A (es)
UY (1) UY38625A (es)
WO (1) WO2020201080A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220348595A1 (en) * 2021-04-09 2022-11-03 Endotarget Inc. Compounds and methods for the targeted degradation of estrogen receptors
TW202321219A (zh) 2021-08-11 2023-06-01 大陸商四川海思科製藥有限公司 雜環衍生物及其組合物和藥學上的應用
WO2023116835A1 (zh) * 2021-12-24 2023-06-29 苏州开拓药业股份有限公司 一种具有酰亚胺骨架的多蛋白降解剂
WO2023212599A2 (en) * 2022-04-26 2023-11-02 Endotarget Inc. Compounds and methods for targeted degradation of estrogen receptors
CN114853751B (zh) * 2022-05-13 2024-01-16 郑州大学第一附属医院 一组吩噻嗪类衍生物及其应用
WO2024015406A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Indole derivatives as estrogen receptor degraders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008152394A1 (en) * 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
NO2714752T3 (es) * 2014-05-08 2018-04-21
US10149839B2 (en) * 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
KR102173463B1 (ko) 2016-10-11 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
IL297717A (en) 2016-12-01 2022-12-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法

Also Published As

Publication number Publication date
MX2021011811A (es) 2021-10-22
PE20220131A1 (es) 2022-01-27
KR20210146984A (ko) 2021-12-06
US20220169643A1 (en) 2022-06-02
SG11202110527RA (en) 2021-10-28
CL2021002489A1 (es) 2022-06-03
BR112021019007A2 (pt) 2021-11-30
ECSP21077887A (es) 2021-11-30
CN113646306A (zh) 2021-11-12
IL286461A (en) 2021-10-31
EA202192553A1 (ru) 2022-02-21
WO2020201080A1 (en) 2020-10-08
TW202102497A (zh) 2021-01-16
AR118515A1 (es) 2021-10-20
CO2021013927A2 (es) 2021-10-29
CA3133763A1 (en) 2020-10-08
DOP2021000198A (es) 2021-10-31
JOP20210259A1 (ar) 2023-01-30
EP3947376A1 (en) 2022-02-09
MA55495A (fr) 2022-02-09
AU2020252116A1 (en) 2021-11-11
UY38625A (es) 2020-10-30
AU2020252116B2 (en) 2023-04-27
JP2022526370A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
CR20210532A (es) Protacs que degradan el receptor de estrógeno
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2023003564A (es) Compuestos y su uso en el tratamiento del cancer.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2019010202A (es) Compuestos que interactuan con glicano y metodos de uso.
MX2021009285A (es) Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).
AU2016354007A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX2022007155A (es) Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
NZ788133A (en) Cd73 inhibitors
PH12019502241A1 (en) Berberine alkaloids in the prevention and/or treatments of intestinal disease
MX2021007687A (es) Sales novedosas de degradadores selectivos de receptores de estrogeno.
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
ZA202200331B (en) Naltrexone formulation
PH12020500120A1 (en) Pharmaceutical compositions
MX2022004121A (es) Derivados de homopiperazinil y homopiperidinil quinazolin-4(3h)-ona que tienen actividad multimodal contra el dolor.
CR20210086A (es) Formulaciones de dendrímeros
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
MX2021007150A (es) Compuesto farmaceutico, metodo de fabricacion y uso como agente medicinal.